标题
Momelotinib for the treatment of myelofibrosis with anemia
作者
关键词
-
出版物
Future Oncology
Volume 18, Issue 20, Pages 2559-2571
出版商
Future Medicine Ltd
发表日期
2022-05-23
DOI
10.2217/fon-2022-0276
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX‐IOL study
- (2022) Elena Maria Elli et al. BRITISH JOURNAL OF HAEMATOLOGY
- Hepcidin is elevated in primary and secondary myelofibrosis and remains elevated in patients treated with ruxolitinib
- (2022) Amy Zhou et al. BRITISH JOURNAL OF HAEMATOLOGY
- Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy
- (2022) Claire N. Harrison et al. JOURNAL OF CLINICAL ONCOLOGY
- Momelotinib: an emerging treatment for myelofibrosis patients with anemia
- (2022) Helen T. Chifotides et al. Journal of Hematology & Oncology
- MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic
- (2021) Srdan Verstovsek et al. Future Oncology
- Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia
- (2021) Srdan Verstovsek et al. HAEMATOLOGICA
- Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis
- (2021) John Mascarenhas et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study
- (2021) Francisco Cervantes et al. LEUKEMIA
- Emerging drugs for the treatment of myelofibrosis: phase II & III clinical trials
- (2021) Douglas Tremblay et al. EXPERT OPINION ON EMERGING DRUGS
- Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure
- (2020) Claire N. Harrison et al. AMERICAN JOURNAL OF HEMATOLOGY
- A Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia
- (2020) Aaron T. Gerds et al. BLOOD
- The Myelodepletive Phenotype in Myelofibrosis: Clinical Relevance and Therapeutic Implication
- (2020) Bridget K. Marcellino et al. Clinical Lymphoma Myeloma & Leukemia
- Patient characteristics and outcomes after ruxolitinib discontinuation in patients with myelofibrosis
- (2020) John Mascarenhas et al. JOURNAL OF MEDICAL ECONOMICS
- ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial
- (2020) Stephen T. Oh et al. Blood Advances
- Luspatercept for the treatment of anemia in myelodysplastic syndromes (MDS) and primary myelofibrosis (PMF)
- (2019) Pierre Fenaux et al. BLOOD
- Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis
- (2019) Francesca Palandri et al. CANCER
- Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis
- (2018) Lucia Masarova et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial
- (2018) Claire N Harrison et al. Lancet Haematology
- Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis
- (2018) John Mascarenhas et al. JAMA Oncology
- SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor–Naïve Patients With Myelofibrosis
- (2017) Ruben A. Mesa et al. JOURNAL OF CLINICAL ONCOLOGY
- NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018
- (2017) Ruben A. Mesa et al. Journal of the National Comprehensive Cancer Network
- Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis
- (2017) A Pardanani et al. LEUKEMIA
- Development of a harmonized patient-reported outcome questionnaire to assess myelofibrosis symptoms in clinical trials
- (2017) Chad Gwaltney et al. LEUKEMIA RESEARCH
- Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study
- (2017) Claire N Harrison et al. Lancet Haematology
- Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients
- (2016) Paola Guglielmelli et al. AMERICAN JOURNAL OF HEMATOLOGY
- The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies
- (2016) V. Gupta et al. HAEMATOLOGICA
- A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis
- (2016) Vikas Gupta et al. HAEMATOLOGICA
- A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence
- (2016) A Tefferi et al. LEUKEMIA
- The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies
- (2016) V. Gupta et al. HAEMATOLOGICA
- A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis
- (2016) Vikas Gupta et al. HAEMATOLOGICA
- C-X-C motif chemokine 12 influences the development of extramedullary hematopoiesis in the spleens of myelofibrosis patients
- (2015) Xiaoli Wang et al. EXPERIMENTAL HEMATOLOGY
- Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis
- (2015) Animesh Pardanani et al. JAMA Oncology
- Momelotinib treatment-emergent neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosis
- (2014) Ramy A. Abdelrahman et al. BRITISH JOURNAL OF HAEMATOLOGY
- Use of the Functional Assessment of Cancer Therapy−Anemia in Persons with Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia
- (2014) Ayalew Tefferi et al. CLINICAL THERAPEUTICS
- Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis
- (2014) Rajasekhar N V S Suragani et al. NATURE MEDICINE
- Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis
- (2013) Animesh Pardanani et al. AMERICAN JOURNAL OF HEMATOLOGY
- Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report
- (2013) A. Tefferi et al. BLOOD
- Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
- (2013) A Pardanani et al. LEUKEMIA
- One Thousand Patients With Primary Myelofibrosis: The Mayo Clinic Experience
- (2012) Ayalew Tefferi et al. MAYO CLINIC PROCEEDINGS
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- Perturbation of hepcidin expression by BMP type I receptor deletion induces iron overload in mice
- (2011) A. U. Steinbicker et al. BLOOD
- Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903
- (2010) R. A. Mesa et al. BLOOD
- CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms
- (2010) J. W. Tyner et al. BLOOD
- Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS
- (2010) C. Elena et al. HAEMATOLOGICA
- CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients
- (2009) A Pardanani et al. LEUKEMIA
- New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
- (2008) F. Cervantes et al. BLOOD
- Risk factors for leukemic transformation in patients with primary myelofibrosis
- (2008) Jocelin Huang et al. CANCER
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started